Cancer Research UK logo.
SearchDonate
  • Search

A trial looking at treatment for adults with primary thrombocythaemia (PT1)

Overview

Cancer types:

Blood cancers, Thrombocythaemia

Status:

Closed

Phase:

Phase 3

Details

This trial is looking at treatment to control symptoms of primary thrombocythaemia (PT).

Primary thrombocythaemia is a condition which causes too many platelets to be made in the bone marrow. It increases the risk of developing blood clots or having a stroke. There is a small chance that primary thrombocythaemia may develop into a cancer of the white blood cells (leukaemia).

Doctors can treat PT with drugs such as aspirin and a drug called hydroxycarbamide (used to be called hydroxyurea).

The aim of this trial is to follow people who have been diagnosed with PT and collect information about the condition and the side effects of treatment.

Recruitment start: 1 June 1997

Recruitment end: 30 April 2013

How to join

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Professor Tony Green

Dr Claire Harrison

Supported by

Cambridge University Hospitals NHS Foundation Trust

Cancer Research UK

Experimental Cancer Medicine Centre (ECMC)

Medical Research Council (MRC)

NIHR Clinical Research Network: Cancer

University of Cambridge

Last reviewed: 21 Jul 2016

CRUK internal database number: 57

The Dangoor Education logo.

Dangoor Education

About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education

Patient Information Forum. Trusted Information Creator.
Plain English Campaign award.

Help and support

An icon of a hand shake.

Find a Clinical Trial

Search our clinical trials database for all cancer trials and studies recruiting in the UK.

An icon of two speech bubbles, indicating a conversation.

Cancer Chat forum

Connect with other people affected by cancer and share your experiences.

An icon of a landline phone.

Nurse helpline

Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.